IN8bio, Inc.
INAB
$1.75
-$0.03-1.69%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -31.81% | -23.18% | -28.17% | -14.50% | -19.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.33% | -40.14% | -34.53% | -21.49% | -15.73% |
| Operating Income | 34.33% | 40.14% | 34.53% | 21.49% | 15.73% |
| Income Before Tax | 45.61% | 40.97% | 35.18% | 18.93% | 1.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 45.61% | 40.97% | 35.18% | 18.93% | 1.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.61% | 40.97% | 35.18% | 18.93% | 1.16% |
| EBIT | 34.33% | 40.14% | 34.53% | 21.49% | 15.73% |
| EBITDA | 35.32% | 43.60% | 37.04% | 23.23% | 16.90% |
| EPS Basic | 81.09% | 77.54% | 66.39% | 63.59% | 34.11% |
| Normalized Basic EPS | 77.74% | 77.54% | 66.39% | 63.59% | 44.04% |
| EPS Diluted | 81.09% | 77.54% | 66.39% | 63.59% | 34.11% |
| Normalized Diluted EPS | 77.74% | 77.54% | 66.39% | 63.59% | 44.04% |
| Average Basic Shares Outstanding | 187.67% | 162.87% | 92.85% | 122.65% | 50.01% |
| Average Diluted Shares Outstanding | 187.67% | 162.87% | 92.85% | 122.65% | 50.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |